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Summary
 Background Infectious complications are a major cause of morbidity and mortality in paedi-
atric and adult patients undergoing haematopoietic stem cell transplantation 
(HSCT).
 Aim Analysis of strategies for prevention of infectious complications in children after 
HSCT in relation to the type of transplantation and GVHD occurrence.
 Materials/Methods A review of PubMed references based on evidence-based recommendations rat-
ed by the strength of the recommendation and the quality of the supporting evi-
dence. The risk of infection was divided into: low for autologous HSCT, moderate 
for MSD-HSCT without GVHD, and high for unrelated, mismatched, haploiden-
tical HSCT, cord blood HSCT, patients with moderate-to-severe GVHD, under-
going immunosuppressive treatment, CMV infection, ex vivo T-cell depletion or 
CD34 selection and in vivo T-cell depletion.
 Results Prophylaxis strategy includes general infection control in hospital environment 
and pharmacological approach, related to antibacterial, antifungal and antiviral 
agents. Most studies were done on adult patients only, while some included both 
paediatric and adults patients. However, no differences in prophylaxis strategy and 
efﬁ cacy between age groups were reported in these studies. Recommendations 
for use of speciﬁ c drugs in prophylaxis in transplantation period and recommen-
dations for vaccination are presented in this paper.
 Conclusions With changing practices, transplant teams are encouraged to review local patterns 
of infections and associated complications and communicate regularly with in-
fection control committees for guidance on the evolution of isolation needs for 
the immunosuppressed patient before and after HSCT.
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BACKGROUND
Infectious complications are a major cause of 
morbidity and mortality in paediatric and adult 
patients undergoing haematopoietic stem cell 
transplantation (HSCT). The incidence and the 
severity code of infections depend on the func-
tion of the host’s immune system. This function 
is strongly correlated with the application of im-
munosuppressive therapy and the time of im-
mune reconstitution after HSCT. The risk of in-
fection is higher in patients after allogeneic than 
autologous transplantation, and in patients with 
GVHD than without it. Patients with GVHD have 
severe immunological deﬁ ciencies due to the dis-
ease and the therapy itself. The risk of infection 
is higher in patients with delayed immune recon-
stitution, especially after haploidentical and cord 
blood transplantation (Table 1). Host defences 
compromised by HSCT that make patients vul-
nerable to infections can be divided into an ear-
ly (before day +30), intermediate (days 30–100) 
and a late phase (after day +100). Each phase 
is related to increased risk of speciﬁ c complica-
tions and speciﬁ c infections that occur at varia-
ble frequency, but each of them carries relative 
life-threatening potential [1].
AIM
Review and analysis of strategies and recommen-
dations for prevention of infectious complications 
in children after HSCT in relation to the type of 
transplantation and GVHD occurrence.
METHODS OF DATA COLLECTION
References were retrieved using the online 
database of the National Library of Medicine 
(PubMed; http://www.ncbi.nlm.nih.gov/PubMed) 
up to October 2006 (with emphasis on the latest 
randomized clinical trial reports). Terms used in-
cluded: haematopoietic stem cell transplantation, 
infection, prophylaxis, strategy, guidelines, rand-
omized clinical trials (RCT), meta-analysis, chil-
dren, vaccination. The retrieved references were 
supplemented by references from the author’s 
own database. The presented strategy is based on 
evidence-based recommendations (Table 2) rat-
ed by the strength of the recommendation and 
the quality of the supporting evidence [1].
RESULTS
Determination of the risk for infection in specif-
ic patient populations is accomplished by eval-
uating various risk factors (exposure, state of 
immunosuppression and organ damage). For 
practical purposes, risk groups of infection af-
ter HSCT with respect to the type of transplan-
tation can be divided into: (A) Low risk: autolo-
gous HSCT; (B) Moderate risk: MSD-HSCT with 
no GVHD (myeloablative, low-toxicity, reduced-
intensity conditioning); (C) High risk: unrelat-
ed, mismatched, haploidentical HSCT (including 
cord blood HSCT), patients with moderate-to-
severe GVHD, undergoing treatment with im-
munosuppressive agents (e.g. corticosteroids), 
CMV infection, ex vivo T-cell depletion or CD34 
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Infection
Relative frequency
Auto-HSCT
Allogeneic 
HSCT without 
GVHD
Allogeneic 
HSCT with 
GVHD
Intermediate phase
Staphylococci + ++ ++
Fungi + ++ +++
Gram-negative 
bacilli – – +
CMV + ++ +++
Late phase
Encapsulated 
bacteria – – ++
Fungi – – +
Table 1. Infections encountered after engraftment in intermediate 
and late phase of immunological recovery [2,3].
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selection of the allograft, in vivo T-cell deple-
tion with ATG, anti-CD52 or ﬂ udarabine [2–4]. 
Multivariate analysis identiﬁ ed the use of ster-
oids as the most signiﬁ cant variable associated 
with infectious episodes. Peripheral blood HSCT 
was associated with more infections in the post-
engraftment period [5].
A. General infection control in hospital 
environment
Sources of infectious agents both in hospitals and 
in houses include mainly: air, dust, construction 
area, ventilation system, potted plants, ﬂ owers, 
cereals, nuts, spices, carpets and water with sec-
ondary aerosolization.
Intensive infection control measures that include 
isolation of patients within protective hospital en-
vironments have become a standard practice dur-
ing allogeneic stem cell transplantation. There 
are no studies indicating the role and range of 
environment control with respect to autologous 
HSCT. The foremost principle of infection proph-
ylaxis is minimization of the possibility that en-
counters with the health care team and expo-
sure to the hospital environment place patients 
at greater risk for acquired infection.
General recommendations for the prevention of 
opportunistic infections in HSCT recipients in-
clude a wide range of interventions related to the 
management of: ventilation systems, BMT unit 
construction and cleaning, isolation and barrier 
precautions, interactions with health-care work-
ers and visitors, skin and oral care, infection sur-
veillance, and the prevention of speciﬁ c nosoco-
mial and seasonal infections. Isolation procedure 
is essential for all allogeneic HSCT patients who 
must enter the system aimed at reducing expo-
sure to contagious agents, which includes: (a) 
Preventing dust accumulation by cleaning all sur-
faces, isolating patient care wards from outside 
air (recommendation AII), maintaining positive 
room pressure and providing patients with masks 
when moving into unprotected areas (BIII); (b) 
Stay in rooms with greater than 12 air exchang-
es per hour with high-efﬁ ciency particulate air 
(HEPA) ﬁ lters (AII) capable of removing particles 
>0.3 μm in diameter; (c) Investigating potential 
outbreaks; (d) Avoiding patient exposure to tap 
water during severe immunosuppression, using 
sponge baths instead of showers and cleaning the 
showering facility prior to use. Measures to reduce 
hospital-acquired candidal infections in these pa-
tients rely on hand washing (AIII), an important, 
simple and inexpensive infection control strategy 
[6]. These practices should also be implement-
ed both before and after patients’ discharge, with 
stress on avoiding risk of environmental exposure 
and decontamination of food (CIII).
B. Pharmacological preventive strategies
Antibacterial primary prophylaxis
During the neutropenic period, the risk of infec-
tion is comparable regardless of HSCT type; thus 
antibacterial prophylaxis should be adjusted to 
the length of neutropenia and mucosal injury. 
Mucositis is usually lower in RIC and low-toxicity 
conditioning, so risk of infection is decreased in 
these HSCTs. The advantage of use of cotrimoxa-
zol and quinolones in antibacterial prophylaxis in 
neutropenia after allo-HSCT in RCT and meta-anal-
yses has been documented (AI) [7,8]. Widely used 
prophylaxes include quinolones, which decrease 
the risk of G-infection, but not mortality [9,10]. 
After both allo- and auto-HSCT, prophylaxis with 
oral penicillin derivatives is compulsory (AI) against 
encapsulated G+ bacteria (Table 3) [11].
Antifungal prophylaxis
Antifungal prophylaxis should be based on risk 
stratiﬁ cation. High-risk group patients obviously 
Category defi nition to determine strength
of recommendation
Category defi nition to determine quality
of supporting evidence
A. Should always be off ered
B. Should generally be off ered
C. Optional
D. Should generally not be off ered
E. Should never be off ered
I. Evidence from at least 1 properly randomized, controlled trial.
II.  Evidence from at least 1 well-designed clinical trial without randomization, from 
cohort or case-controlled analytic studies (preferably from more than 1 centre), or 
from multiple time-series or dramatic results from uncontrolled experiments.
III.  Evidence from opinions of respected authorities based on clinical experience, 
descriptive studies or reports of expert committees.
Table 2. Evidence-based rating system used to determine strength and quality of supporting evidence for recommendations of HSCT 
guidelines.
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should be given antifungal prophylaxis. There is 
no recommendation for antifungal prophylaxis in 
all patients in the low-risk group. The most con-
troversial is the moderate group, which is a heter-
ogeneous group. It is believed that those patients 
should be offered antifungal prophylaxis or fre-
quent HRCT and laboratory screening.
Transplantation strategies that reduce the du-
ration and degree of mucosal injury, the du-
ration of myeloid, macrophage and Th1-type 
immunodeﬁ ciency, the severity of GVHD, and 
the need for corticosteroids, parenteral nutri-
tion or intravenous catheters, would all contrib-
ute to a decrease in invasive fungal infections. 
Candida spp. is a mucocutaneous commensur-
al organism and violating the integrity of these 
surfaces is directly related to the risk for infec-
tion. Outbreaks of candidal infections have also 
been associated with transmission via the skin 
and nails of healthcare workers. In contrast, the 
incidence of aspergillus has been shown to be 
related to environmental exposures, which may 
have occurred prior to the diagnosed infection 
[3]. Central to the prevention of aspergillosis 
is the avoidance of inhalation of spores. In the 
outpatient setting, there are no proven meth-
ods to decrease risk of colonization. Avoidance 
of contact with soil and plants, gardening, or 
maintenance of compost piles would be pru-
dent (AII). The optimal duration of this prohi-
bition is not clear [6,29].
Administration of ﬂ uconazole 2×200 mg until 
day +75 (both in children and adults, Table 3) 
decreases the risk of infection and mortality with 
Candida albicans [30]. Prophylaxis against moulds 
is accepted with relevant active agents only as sec-
ondary prophylaxis. There is a lack of RCT, but it 
seems that posaconazole, voriconazole, ampho-
tericine and ecchinocandines are of important 
value [20,31]. The value of itaconazole is dimin-
ished by limited oral availability and more ad-
verse effects [32,33]. The duration of anti-mould 
prophylaxis remains to be established, as median 
time to invasive aspergillosis far exceeds day +100 
[34]; thus immunological recovery at 1 year after 
HSCT in patients without GVHD might be rec-
ommended as the end of prophylaxis.
Antiviral primary prophylaxis
CMV: The preventive strategies for CMV disease 
include the use of appropriate blood products, 
and use of antiviral agents either as chemoproph-
ylaxis or pre-emptive therapy (AI). There are two 
general approaches to prevention of CMV disease, 
using either gancyclovir or foscarnet: (a) treat-
ment of all at-risk patients for the deﬁ ned period 
of risk as pre-emptive therapy, and (b) treatment 
Prophylaxis Indication First and second recommendation Beginning End
Antibacterial All patients Ciprofl oxacin (AI)Ofl oxacin, Levofl oxacin [11] Conditioning Engraftment
Pneumocystis jiroveci All patients Cotrimoxazole (AII)Pentamidine [12–14]
Conditioning/
Engraftment
End of IST or GVHD 
(>6 months)
Yeasts All patients Fluconazol (AI)Itraconazole [15,16]
Conditioning,
I: Day +1 Day +75
Moulds Secondary prophylaxis [AIII]
Posaconazole, Voriconazole, Itraconazole, 
Micafungin [4,17–21]
Conditioning,
I: Day +1
At the earliest of 
engraftment
CMV High-risk patients Ganciclovir (AI)Foscarnet, Cidofovir [22,23] Engraftment Day +100
HSV IgG positive patients Acyclovir (AI)Valacyclovir [24–26] Day +1 Day +30
VZV Secondary prophylaxis AcyclovirValacyclovir [27] Day +1 End of IST or GVHD
Toxoplasmosis Secondary prophylaxis CotrimoxazoleClindamycine or pyrimethamine+LV [28] Conditioning End of IST
Vaccinations All patients (AIII)  6-12 months  
Table 3. Recommendations for antimicrobial prophylaxis.
IST – immunosuppressive therapy.
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of early blood-borne CMV infection prior to onset 
of disease. Pre-emptive therapy is the most com-
mon and effective prophylactic strategy in pa-
tients with CMV reactivation. Intravenous ganci-
clovir prophylaxis is an effective strategy for the 
prevention of CMV disease and could be used in 
subgroups of allogeneic HSCT patients at high 
risk for CMV disease (AI) [22,23,35]. Oral val-
ganciclovir could be a useful alternative to intra-
venous ganciclovir [36,37]. In randomized stud-
ies both acyclovir and valacyclovir were shown to 
reduce the risk of CMV infection, but not CMV 
disease [38,39]. However, their use must be com-
bined with CMV monitoring and preemptive ther-
apy (AI). Intravenous immunoglobulin (IGIV) 
for the prevention of CMV infection or disease 
is not recommended (DII) [40]. New concepts 
in CMV prophylaxis in a selected group of pa-
tients include immunotherapy with donor T lym-
phocytes sensitized to CMV antigens, but this is 
still an experimental approach.
Other herpes viruses: Prophylaxis against Herpes 
simplex (HSV) with acyclovir should be intro-
duced in seropositive patients only, in –1 to +30 
days (Table 3). Acyclovir effectively and safely 
prevents VZV disease during the ﬁ rst year after 
haematopoietic cell transplantation. Periods of 
prophylaxis longer than 12 months may be ben-
eﬁ cial for those haematopoietic cell transplant 
recipients on continued immune suppression. 
Acyclovir signiﬁ cantly reduced VZV infections at 
1 year after transplantation [41]. For other her-
pes viruses there are no standard pharmacolog-
ical recommendations, as reviewed by Kruger et 
al. [19]. Prospective studies are needed to fur-
ther examine management strategies for these 
viruses.
C. Vaccination strategy
Vaccination is a potentially important strategy 
for reducing the risk for vaccine-preventable in-
fections after SCT. The EBMT recommendations 
for vaccination of HSCT recipients published in 
Bone Marrow Transplantation in 1995 and in 
2005 [42] updated with current knowledge are 
presented in Table 4.
 Type of vaccine Beginningof vaccination Doses Indications Recommendations
Viral
Infl uenza Inactivated 4–6 1 Every year AII [44]
Polio Inactivated 6–12 3 Yes BII [45]
Hepatitis B* Inactivated 6–12 3 Yes BII [46]
Hepatitis A Inactivated 6–12 3 Optional CIII [42]
MMR Alive 24 1 Individually BII / CII [47]
Varicella Alive 24 1? Optional CIII [48, 49]
Yellow fever Alive 24 (or before) 1 Optional CIII 
Bacterial      
H. infl uenzae B* Conjugated 6 3 Yes BII [50, 51]
N. meningitidis A i C Polysaccharide 6–12 1 Optional CII [52]
N. meningitidis C Conjugated 6 1 Optional CIII [42]
Tetanus* Toxoid 6–12 3 Yes BII [53]
Diptheria Toxoid 6–12 3 Yes BII [42]
Bordetella pertusis Acellular 6–12 3 Optional CIII [42]
S. pneumoniae Polysaccharide 12 1 Yes BII [49, 54]
S. pneumoniae * Conjugated ? 3 Yes AII [55-57]
Tuberculosis Alive No 0 No EII [58]
Table 4. Recommendations for vaccinations after stem cell transplantation [42,43].
* recommended donor vaccination.
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There are new data indicating the beneﬁ t of do-
nor vaccination before HSCT. This is of proven 
value for prophylaxis of infections with viral hep-
atitis B [59,60], Haemophilus inﬂ uenzae [50,51], 
Streptococcus pneumoniae with conjugated vaccine 
[55,56] and tetanus [61]. In all cases, early recip-
ient vaccination post-HSCT is recommended.
DISCUSSION
Most studies were done on adult patients only, 
while some included both paediatric and adult 
patients; however, no differences in prophylaxis 
strategy or efﬁ cacy between age groups were re-
ported in these studies.
Local conditions, microbiological characteris-
tic and patient situation should decide the spe-
ciﬁ c pharmacological prophylaxis. This con-
cerns ﬁ rst of all antifungal prevention, but may 
play a key role also in antibacterial and antiviral 
prophylaxis. Hand washing is of utmost impor-
tance to avoid transmission of infectious agents 
from one patient to another and from staff to 
patients. Avoidance of any exposure to infection 
and decontamination of food are always very im-
portant practices. Bacterial surveillance cultures 
have been found to be useful in detecting anti-
biotic-resistant bacteria [62].
Apart from general control and pharmacological 
strategy, adjunctive measures like growth factors, 
IGIV supplementation and granulocyte transfu-
sions might have an important role in infection 
prophylaxis. Controlled trials of administrations of 
haematopoietic growth factor G-CSF have failed to 
show improved outcome in either HSCT [63] or 
non-HSCT neutropenic patients, other than short-
ening of neutropenia duration and antibiotic uti-
lization. Keratinocyte growth factors have abilities 
to enhance mucosal stem cell growth and decrease 
local injury [64]. IGIV is regarded not to show ben-
eﬁ t, both in autologous HSCT [65] and in MSD-
HSCT patients [5]. Modest, but signiﬁ cant, bene-
ﬁ t of G-CSF-mobilized HLA-matched prophylactic 
granulocyte transfusions, expressed by reduction of 
febrile days and intravenous antibiotic usage, was 
demonstrated in neutropenic allogeneic HSCT re-
cipients, but it is still controversial [66].
CONCLUSIONS
With changing practices, transplant teams are 
encouraged to review local patterns of infec-
tions and associated complications and commu-
nicate regularly with infection control commit-
tees for guidance on the evolution of isolation 
needs for the immunosuppressed patient before 
and after HSCT.
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